8-K: Calidi Biotherapeutics Settles Stock Option Dispute, Issues Shares and Warrants

Calidi Biotherapeutics has reached a settlement agreement regarding a dispute over stock options, issuing restricted shares and warrants to the involved physicians.

Summary

• Calidi Biotherapeutics settled a dispute with a group of physicians regarding stock options and a terminated partnership agreement.
• The physicians had claimed that 1,248,600 vested stock options were still valid despite the termination of their services in 2018.
• As part of the settlement, Calidi issued 200,000 restricted shares of common stock and 400,000 warrants to purchase shares at an exercise price of $1.32.
• The warrants are exercisable for 5 years from the date of issuance.
• The physicians also received piggy-back registration rights for the restricted shares and any shares issued upon exercise of the warrants.
• Calidi retains the right to refuse registration if it would negatively impact their ability to raise capital.

Sentiment

Score: 6

Explanation: The settlement resolves a legal issue, which is positive, but the issuance of shares and warrants will dilute existing shareholders, which is a negative. The overall sentiment is neutral to slightly positive.

Positives

• The settlement resolves a legal dispute, removing uncertainty related to the stock options.
• The agreement provides a clear path forward for both Calidi and the physicians.
• The issuance of shares and warrants is a defined cost to resolve the dispute.

Negatives

• The issuance of 200,000 restricted shares and 400,000 warrants will dilute existing shareholders.
• The piggy-back registration rights could potentially impact future capital raising efforts if exercised.

Risks

• The potential dilution of existing shares due to the issuance of new shares and warrants.
• The risk that piggy-back registration rights could complicate future capital raising efforts.
• The possibility that the company may need to refuse registration of the shares and warrants if it impacts capital raising.

Future Outlook

The company has the right to refuse to register the Restricted Shares and Warrant Shares if it determines, in its sole discretion based on commercially reasonable grounds, that the inclusion of the Restricted Shares and Warrant Shares pursuant to piggy-back rights will adversely affect our ability to raise capital from such registration statement.

Management Comments

• Andrew Jackson, Chief Financial Officer, signed the report on behalf of Calidi Biotherapeutics.

Industry Context

Settlements of legal disputes are common in the biotech industry, especially those involving stock options and partnership agreements. This settlement allows Calidi to move forward without the distraction of ongoing litigation.

Comparison to Industry Standards

• The issuance of shares and warrants to settle disputes is a common practice in the biotech industry.
• The terms of the settlement, including the exercise price and duration of the warrants, appear to be within industry norms.
• Piggy-back registration rights are also a standard feature in such agreements, although the company's right to refuse registration is a protective measure.

Legal Proceedings

• The document details the settlement of a lawsuit filed by the physicians against Calidi Biotherapeutics.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares and warrants.
• The physicians involved in the dispute will receive shares and warrants as part of the settlement.
• The settlement removes uncertainty for all stakeholders.

Next Steps

• The company will issue the restricted shares and warrants to the physicians.
• The company will monitor the potential impact of piggy-back registration rights on future capital raising efforts.

Key Dates

Keywords

settlement, stock options, warrants, restricted shares, piggy-back rights, legal dispute, capital raise, dilution